Summary
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades.
For the purposes of this report, we consider the Global SCLC market to include SCLC-specific drug sales in the 7MM (US, 5EU [France, Germany Italy, Spain, and the UK], and Japan). The current market across these countries is dominated by the sale of major generic chemotherapy regimens. GlobalData estimated that the Global SCLC market was valued at $198m in 2014. Following the expected approval of new agents over the forecast period, relapsed/refractory patients will have significantly improved therapeutic options leading to rapid uptake of these drugs. The increased use of branded therapies in treatment-naïve and advanced patients, such as Yervoy, Opdivo, roniciclib, and sacituzumab govitecan, will be the primary driver of the substantial growth in the SCLC market over the forecast period, which is expected to grow at a positive CAGR of almost 28% in the 7MM.
Highlights
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the SCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?
- What research and development (R&D) strategies will companies leverage to compete in the future SCLC marketplace?
- Which pipeline products are poised to make a major clinical and commercial impact?
- What clinical and commercial factors are likely to influence SCLC drug uptake in the 7MM?
Key Findings
- The greatest driver of growth within the Global SCLC market will be the launch and increased use of premium-priced therapies, including anti-PD-1 immunotherapy and targeted agents such as roniciclib and sacituzumab govitecan. GlobalData expects Yervoy to reach blockbuster status by the end of the forecast period, with global sales of around $1bn.
- Continuous dosing regimens until disease progression and adoption of maintenance setting following induction therapy for first-line patients will contribute to the increased sales of branded drugs.
- Toxicity is likely to remain a major concern as new first-line treatment options are approved considering companies are developing them in combination with platinum-etoposide. Therefore, substantial opportunity remains to develop therapies that have improved safety profiles compared with agents in the current SCLC pipeline.
- An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of SCLC pipeline agents. GlobalData expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new SCLC therapies.
Scope
- Overview of SCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Topline SCLC drug market revenue from 2014-2024, annual cost of therapy (ACOT), and major product sales in six patient segments during the forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the SCLC market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global SCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SCLC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
'
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Diagnosis
3.4 Clinical Staging
3.5 Prognostic Factors
3.6 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Incidence
4.3.2 Stage at Diagnosis
4.3.3 Relative Survival
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for SCLC (2014-2024)
4.5.1 Diagnosed Incident Cases of SCLC
4.5.2 Age-Specific Incident Cases of SCLC
4.5.3 Sex-Specific Incident Cases of SCLC
4.5.4 Age-Standardized Incidence of SCLC
4.5.5 Stage-Specific Incident Cases of SCLC
4.5.6 Five-Year Diagnosed Prevalent Cases of SCLC
4.5.7 Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.1 First-Line Therapy
5.2 Second-Line Therapy
5.3 Subsequent Lines of Therapy
6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 Unmet Needs Analysis
6.2.1 Early Diagnosis of Disease
6.2.2 Therapies That Improve Overall Survival
6.2.3 More Effective and Tolerable Therapies for Relapsed/Refractory Disease
6.2.4 Discovery of Predictive Biomarkers and Understanding of the Underlying Causes of Disease
6.2.5 Smoking Cessation Programs
6.3 Opportunity Analysis
6.3.1 Standardized Methods for Biomarker Testing
6.3.2 Developing Therapies with an Improved Safety Profile
6.3.3 Understanding the Mechanisms Underlying the Rapid Emergence of Drug and Radiation Resistance
6.3.4 Targeting Pathways Unique to Cancer Stem Cells
7 R&D Strategies
7.1 Overview
7.1.1 Deconstructing the SCLC Genome
7.1.2 New Diagnostic Approaches
7.1.3 Reformulation of Available Chemotherapeutic Agents
7.1.4 Combination Therapy
7.2 Clinical Trial Design
7.2.1 Evolution of Endpoints for Cancer Immunotherapy Trials
7.2.2 Health-Related Quality of Life Endpoints in Oncology Clinical Trials
7.2.3 Design of Current Phase II and III Trials in SCLC
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 Alisertib (MLN8237)
8.2.2 MGN-1703
8.2.3 NGR-hTNF
8.2.4 Opdivo (nivolumab)
8.2.5 Roniciclib (BAY 1000394)
8.2.6 Sabarubicin (MEN10755)
8.2.7 Sacituzumab Govitecan (IMMU-132)
8.2.8 Sutent (sunitinib malate)
8.2.9 Tarextumab (OMP-59R5)
8.2.10 Yervoy (ipilimumab)
8.3 Innovative Early-Stage Approaches
8.3.1 Rovalpituzumab Tesirine (SC16LD6.5)
8.3.2 Keytruda (pembrolizumab)
8.3.3 PARP Inhibitors
8.3.4 Lurbinectedin (PM01183)
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top-Line 10-Year Forecast
9.4.1 US
9.4.2 5EU
9.4.3 Japan
10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Methodology
10.4 Forecasting Methodology
10.4.1 Diagnosed SCLC Patients
10.4.2 Percent Drug-Treated Patients
10.4.3 Drugs Included in Each Therapeutic Class
10.4.4 Launch and Patent Expiry Dates
10.4.5 General Pricing Assumptions
10.4.6 Average Body Weight and Surface Area Across 7MM
10.4.7 Individual Drug Assumptions
10.4.8 Generic Erosion
10.5 Physicians and Specialists Included in this Study
10.6 About the Authors
10.6.1 Authors
10.6.2 Epidemiologist
10.6.3 Global Director of Therapy Analysis and Epidemiology
10.6.4 Global Head of Healthcare
10.7 About Us
10.8 Disclaimer
1.1 List of Tables
Table 1: Symptoms of Neurologic and Endocrine Paraneoplastic Syndromes in SCLC
Table 2: AJCC TNM Classification System for Small Cell Lung Cancer
Table 3: AJCC TNM Staging System for Small Cell Lung Cancer
Table 4: Risk Factors and Comorbidities Associated with SCLC
Table 5: 7MM, Sources Used for Diagnosed Incidence of SCLC, 2014
Table 6: 7MM, Sources Used for Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis
Table 7: 7MM, Sources Used for the Five-Year Diagnosed Prevalent Cases of LS-SCLC
Table 8: 7MM, Sources Used for the Five-Year Relative Survival of ES-SCLC
Table 9: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages =18 Years, Select Years, 2014-2024
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages =18 Years, N (Row %), 2014
Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of SCLC, Ages =18 Years, N (Row %), 2014
Table 12: 7MM, Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis, Ages =18 Years, N, 2014
Table 13: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages =18 Years, Select Years, 2014-2024
Table 14: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage at Diagnosis, Ages =18 Years, N, 2014
Table 15: The Efficacy of Chemotherapeutic Agents in the First-Line Treatment of SCLC
Table 16: The Efficacy of Various TRT Regimens in SCLC
Table 17: The Efficacy of PCI in SCLC
Table 18: The Efficacy of Chemotherapeutic Agents in the Second-Line Treatment of SCLC
Table 19: Overall Unmet Needs - Current Level of Attainment
Table 20: Genes of Interest in SCLC
Table 21: Clinical Development of Potential Biomarkers for SCLC
Table 22: Potential Surrogate Endpoints by Disease Stage
Table 23: Design of Current Clinical Trials in the First-Line Treatment of SCLC
Table 24: Design of Current Clinical Trials in the Second-Line Treatment of SCLC
Table 25: Product Profile - Alisertib (MLN8237)
Table 26: Efficacy of Alisertib in Relapsed/Refractory SCLC
Table 27: Safety of Alisertib in Relapsed/Refractory SCLC
Table 28: Alisertib (MLN8237)
Table 29: Global Sales Forecast ($m) for Alisertib, 2014-2024
Table 30: Product Profile - MGN-1703
Table 31: Efficacy of MGN-1703 in Heavily Pretreated Patients with Metastatic Solid Tumors
Table 32: MGN-1703
Table 33: Product Profile - NGR-hTNF
Table 34: Efficacy of NGR-hTNF in Combination with Doxorubicin in Relapsed/Refractory SCLC
Table 35: NGR-hTNF
Table 36: Global Sales Forecast ($m) for NGR-hTNF, 2014-2024
Table 37: Product Profile - Opdivo
Table 38: Efficacy of Nivolumab Monotherapy and Nivolumab + Ipilimumab in Relapsed/Refractory
Table 39: Safety of Nivolumab Monotherapy and Nivolumab + Ipilimumab in Relapsed/Refractory SCLC
Table 40: Opdivo (nivolumab) SWOT Analysis
Table 41: Global Sales Forecast ($m) for Opdivo, 2014-2024
Table 42: Product Profile - Roniciclib (BAY 1000394)
Table 43: Efficacy of Roniciclib (BAY 1000394) in ES-SCLC
Table 44: Safety of Roniciclib (BAY 1000394) in ES-SCLC
Table 45: Roniciclib (BAY 1000394) SWOT Analysis
Table 46: Global Sales Forecast ($m) for Roniciclib, 2014-2024
Table 47: Product Profile - Sabarubicin (MEN10755)
Table 48: Efficacy of Sabarubicin + Cisplatin in ES-SCLC
Table 49: Safety of Sabarubicin + Cisplatin in ES-SCLC
Table 50: Sabarubicin (MEN10755) SWOT Analysis
Table 51: Product Profile - Sacituzumab Govitecan (IMMU-132)
Table 52: Efficacy of IMMU-132 in Relapsed/Refractory SCLC
Table 53: Safety of Sacituzumab Govitecan (IMMU-132) in Relapsed/Refractory SCLC
Table 54: Sacituzumab Govitecan (IMMU-132) SWOT Analysis
Table 55: Global Sales Forecast ($m) for Sacituzumab Govitecan, 2014-2024
Table 56: Product Profile - Sutent (Sunitinib Malate)
Table 57: Efficacy of Sutent Maintenance Therapy Following Chemotherapy in ES-SCLC
Table 58: Sutent (Sunitinib Malate)
Table 59: Global Sales Forecast ($m) for Sutent, 2014-2024
Table 60: Product Profile - Tarextumab (OMP-59R5)
Table 61: Safety of Tarextumab in ES-SCLC
Table 62: Tarextumab (OMP-59R5)
Table 63: Global Sales Forecast ($m) for Tarextumab, 2014-2024
Table 64: Product Profile - Yervoy
Table 65: Efficacy of Concurrent- and Phased-Ipilimumab in ES-SCLC
Table 66: Safety of the Concurrent- and Phased-Ipilimumab in Combination with Paclitaxel + Carboplatin in ES-SCLC
Table 67: Yervoy (ipilimumab) SWOT Analysis
Table 68: Global Sales Forecast ($m) for Yervoy, 2014-2024
Table 69: Early-Stage Pipeline Products in SCLC
Table 70: Clinical Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer, First-Line Therapies
Table 71: Clinical Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer, Relapsed/Refractory (R/R) Therapies
Table 72: Commercial Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer
Table 73: Top-Line Sales Forecasts ($m) for SCLC, 2014-2024
Table 74: Key Events Impacting Sales for SCLC, 2014-2024
Table 75: Small Cell Lung Cancer Market in the US - Drivers and Barriers, 2014-2024
Table 76: Small Cell Lung Cancer Market in the 5EU - Drivers and Barriers, 2014
Table 77: Small Cell Lung Cancer Market in Japan - Drivers and Barriers, 2014
Table 78: Key Launch Dates
Table 79: Key Patent/Exclusivity Expiries
Table 80: Average Body Weight and Surface Area Across the 7MM
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages =18 Years, 2014-2024
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages =18 Years, Both Sexes, N, 2014
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of SCLC, Ages =18 Years, N, 2014
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of SCLC, Ages =18 Years, 2014
Figure 5: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages =18 Years, 2014-2024
Figure 6: First-Line Treatment Options for SCLC Based on Staging
Figure 7: Small Cell Lung Cancer - Late-Stage Pipeline, 2015
Figure 8: Alisertib (MLN8237) in SCLC
Figure 9: Design of the Phase I/II Study Investigating the Activity of Alisertib in Relapsed/Refractory SCLC
Figure 10: MGN-1703 in SCLC
Figure 11: Design of the Phase I Study Investigating the Activity of MNG-1703 in Heavily Pretreated Patients with Metastatic Solid Tumors
Figure 12: NGR-hTNF in SCLC
Figure 13: Design of the Phase II Study Investigating the Activity of NGR-hTNF in Combination with Doxorubicin in Relapsed/Refractory SCLC
Figure 14: Opdivo (nivolumab) in SCLC
Figure 15: Design of the Phase I/II CheckMate 032 Study Investigating the Activity of Nivolumab Monotherapy or Nivolumab + Ipilimumab in Relapsed/Refractory SCLC
Figure 16: Roniciclib in SCLC
Figure 17: Design of the Phase Ib/II Study Investigating the Activity of Roniciclib (BAY 1000394) in ES-SCLC
Figure 18: Sacituzumab Govitecan in SCLC
Figure 19: Design of the Phase I/II Study Investigating the Activity of IMMU-132 in Relapsed/Refractory SCLC
Figure 20: Design of the Phase I/II Study Investigating the Activity of Sutent Maintenance Therapy in ES-SCLC
Figure 21: Tarextumab in SCLC
Figure 22: Design of the Phase Ib PINNACLE Study Investigating the Activity of Tarextumab in Combination with Platinum-Etoposide in ES-SCLC
Figure 23: Yervoy (ipilimumab) in SCLC
Figure 24: Design of CA184-041 Phase II Study Investigating the Potential of Concurrent- and Phased-Ipilimumab versus Placebo in Combination with Paclitaxel + Carboplatin in ES-SCLC
Figure 25: Competitive Assessment of Late-Stage Pipeline Agents in SCLC, 2014-2024
Figure 26: Global Sales for SCLC by Region, 2014-2024
1.1 List of Tables
Table 1: Symptoms of Neurologic and Endocrine Paraneoplastic Syndromes in SCLC
Table 2: AJCC TNM Classification System for Small Cell Lung Cancer
Table 3: AJCC TNM Staging System for Small Cell Lung Cancer
Table 4: Risk Factors and Comorbidities Associated with SCLC
Table 5: 7MM, Sources Used for Diagnosed Incidence of SCLC, 2014
Table 6: 7MM, Sources Used for Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis
Table 7: 7MM, Sources Used for the Five-Year Diagnosed Prevalent Cases of LS-SCLC
Table 8: 7MM, Sources Used for the Five-Year Relative Survival of ES-SCLC
Table 9: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages =18 Years, Select Years, 2014-2024
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages =18 Years, N (Row %), 2014
Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of SCLC, Ages =18 Years, N (Row %), 2014
Table 12: 7MM, Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis, Ages =18 Years, N, 2014
Table 13: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages =18 Years, Select Years, 2014-2024
Table 14: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage at Diagnosis, Ages =18 Years, N, 2014
Table 15: The Efficacy of Chemotherapeutic Agents in the First-Line Treatment of SCLC
Table 16: The Efficacy of Various TRT Regimens in SCLC
Table 17: The Efficacy of PCI in SCLC
Table 18: The Efficacy of Chemotherapeutic Agents in the Second-Line Treatment of SCLC
Table 19: Overall Unmet Needs - Current Level of Attainment
Table 20: Genes of Interest in SCLC
Table 21: Clinical Development of Potential Biomarkers for SCLC
Table 22: Potential Surrogate Endpoints by Disease Stage
Table 23: Design of Current Clinical Trials in the First-Line Treatment of SCLC
Table 24: Design of Current Clinical Trials in the Second-Line Treatment of SCLC
Table 25: Product Profile - Alisertib (MLN8237)
Table 26: Efficacy of Alisertib in Relapsed/Refractory SCLC
Table 27: Safety of Alisertib in Relapsed/Refractory SCLC
Table 28: Alisertib (MLN8237)
Table 29: Global Sales Forecast ($m) for Alisertib, 2014-2024
Table 30: Product Profile - MGN-1703
Table 31: Efficacy of MGN-1703 in Heavily Pretreated Patients with Metastatic Solid Tumors
Table 32: MGN-1703
Table 33: Product Profile - NGR-hTNF
Table 34: Efficacy of NGR-hTNF in Combination with Doxorubicin in Relapsed/Refractory SCLC
Table 35: NGR-hTNF
Table 36: Global Sales Forecast ($m) for NGR-hTNF, 2014-2024
Table 37: Product Profile - Opdivo
Table 38: Efficacy of Nivolumab Monotherapy and Nivolumab + Ipilimumab in Relapsed/Refractory
Table 39: Safety of Nivolumab Monotherapy and Nivolumab + Ipilimumab in Relapsed/Refractory SCLC
Table 40: Opdivo (nivolumab) SWOT Analysis
Table 41: Global Sales Forecast ($m) for Opdivo, 2014-2024
Table 42: Product Profile - Roniciclib (BAY 1000394)
Table 43: Efficacy of Roniciclib (BAY 1000394) in ES-SCLC
Table 44: Safety of Roniciclib (BAY 1000394) in ES-SCLC
Table 45: Roniciclib (BAY 1000394) SWOT Analysis
Table 46: Global Sales Forecast ($m) for Roniciclib, 2014-2024
Table 47: Product Profile - Sabarubicin (MEN10755)
Table 48: Efficacy of Sabarubicin + Cisplatin in ES-SCLC
Table 49: Safety of Sabarubicin + Cisplatin in ES-SCLC
Table 50: Sabarubicin (MEN10755) SWOT Analysis
Table 51: Product Profile - Sacituzumab Govitecan (IMMU-132)
Table 52: Efficacy of IMMU-132 in Relapsed/Refractory SCLC
Table 53: Safety of Sacituzumab Govitecan (IMMU-132) in Relapsed/Refractory SCLC
Table 54: Sacituzumab Govitecan (IMMU-132) SWOT Analysis
Table 55: Global Sales Forecast ($m) for Sacituzumab Govitecan, 2014-2024
Table 56: Product Profile - Sutent (Sunitinib Malate)
Table 57: Efficacy of Sutent Maintenance Therapy Following Chemotherapy in ES-SCLC
Table 58: Sutent (Sunitinib Malate)
Table 59: Global Sales Forecast ($m) for Sutent, 2014-2024
Table 60: Product Profile - Tarextumab (OMP-59R5)
Table 61: Safety of Tarextumab in ES-SCLC
Table 62: Tarextumab (OMP-59R5)
Table 63: Global Sales Forecast ($m) for Tarextumab, 2014-2024
Table 64: Product Profile - Yervoy
Table 65: Efficacy of Concurrent- and Phased-Ipilimumab in ES-SCLC
Table 66: Safety of the Concurrent- and Phased-Ipilimumab in Combination with Paclitaxel + Carboplatin in ES-SCLC
Table 67: Yervoy (ipilimumab) SWOT Analysis
Table 68: Global Sales Forecast ($m) for Yervoy, 2014-2024
Table 69: Early-Stage Pipeline Products in SCLC
Table 70: Clinical Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer, First-Line Therapies
Table 71: Clinical Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer, Relapsed/Refractory (R/R) Therapies
Table 72: Commercial Benchmarking of Key Marketed and Pipeline Drugs-Small Cell Lung Cancer
Table 73: Top-Line Sales Forecasts ($m) for SCLC, 2014-2024
Table 74: Key Events Impacting Sales for SCLC, 2014-2024
Table 75: Small Cell Lung Cancer Market in the US - Drivers and Barriers, 2014-2024
Table 76: Small Cell Lung Cancer Market in the 5EU - Drivers and Barriers, 2014
Table 77: Small Cell Lung Cancer Market in Japan - Drivers and Barriers, 2014
Table 78: Key Launch Dates
Table 79: Key Patent/Exclusivity Expiries
Table 80: Average Body Weight and Surface Area Across the 7MM
Abbvie
AstraZeneca
Bayer
BioMarin Pharmaceutical
Bristol Myers Squibb
Cerulean Pharma
GlaxoSmithKline
Immunomedics
Medivation
Menarini
Merck
MolMed
Mologen
OncoMed Pharmaceuticals
Pfizer
Pharma MaR
Stem CentRX
Takeda
